晚期非小细胞肺癌免疫治疗现状及未来方向

肺癌仍然是中国发病率和死亡率最高的恶性肿瘤,其中非小细胞肺癌（non-small cell lung cancer,NSCLC）约占80%以上。以靶向程序性死亡蛋白]-1（programmed death protein-1,PD-1）或程序性死亡蛋白]配体-1（programmed death ligand-1,PD-L1）的免疫检查点抑制剂（immune checkpoint inhibitor,ICI）为基础的治疗已成为了晚期肺癌的标准治疗手段之一。本综述将对晚期NSCLC免疫治疗的现状予以梳理,探讨现阶段面临的问题与挑战,并思考与展望未来发展方向。

Current status and future directions of immunotherapy for advanced non-small cell lung cancer

Lung cancer remains the malignant tumor with the highest morbidity and mortality in China, among which non-small cell lung cancer (NSCLC) accounts for more than 80%. Immune checkpoint inhibitors (ICIs)-based therapy targeting programmed death protein-1 (PD-1) or its ligand programmed death ligand-1 (PD-L1) has become one of the standard treatments for advanced NSCLC. This review, with the focus on advanced NSCLC, summarized the development of immunotherapy, discussed current problems, and challenges and proposed future directions.